This study is in progress, not accepting new patients
A Study of VGL101 in Patients with Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Jeffrey Gelfand
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Jeffrey Gelfand
Dr. Gelfand is a Professor of Neurology at UCSF. He specializes in caring for patients with a wide range of neuroinflammatory and neurodegenerative disorders. Dr. Gelfand conducts clinical research, including clinical trials, focused on advancing new treatments for neuroimmunological diseases and restoring neurological function. Dr. Gelfand is also an award-winning medical educator.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Vigil Neuroscience, Inc.
- ID
- NCT05677659
- Phase
- Phase 2 ALSP Research Study
- Study Type
- Interventional
- Participants
- About 20 people participating
- Last Updated